Antifungal from F2G, Shionogi succeeds in Phase 3 study
Antifungal from F2G, Shionogi succeeds in Phase 3 study Industry developments covered.
F2G
Private
F2G is a clinical-stage biopharmaceutical company developing olorofim, a first-in-class oral antifungal targeting dihydroorotate dehydrogenase (DHODH), with a novel mechanism of action against difficult-to-treat invasive fungal infections including azole-resistant aspergillosis and rare molds. Headquartered in Manchester, UK; partnered with Shionogi for commercialization in APAC.
Company Info
Sector:Small Molecule Pharma (Antifungal)
Headquarters:Manchester, United Kingdom
Founded:1998
Website:f2g.com/
Funding Round:Series funded through 2024-2026 with Shionogi partnership proceeds
Total Funding:$270M+ (cumulative private financings incl. 2022 Nordic and ICG-led rounds)
Funding & Investor Relations
Notable Investors
- GIC
- Morningside Ventures
- Brace Pharma Capital
- Cipio Partners
- Sectoral Asset Management
- Novo Holdings
- AMR Action Fund
IPO Outlook / Plans
Exploring strategic options; not currently public as of mid-2026
Upcoming Milestones & Key Dates
2026 H2
Clinical / Regulatory
OASIS Phase 3 readout and regulatory submissions for olorofim
2026 Q4
Regulatory
Anticipated NDA / MAA submissions for olorofim in invasive aspergillosis
Clinical Development Pipeline
Olorofim (F901318)
Target: Dihydroorotate dehydrogenase (DHODH) inhibitorF2G follow-on antifungal
Target: Undisclosed novel mechanism (early pipeline)APX2039 (research collaboration asset)
Target: Preclinical asset (research-stage)Recent News
Leadership Team
Francesco Maria Lavino
Chief Executive Officer
Dr. John H. Rex
Chief Medical Officer
Careers & Job Openings